As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of AN2 Therapeutics, Inc. The largest reported stake is Commodore Capital LP's, at 9.9%. 7 filings are on record since November 14, 2025 (Schedule 13G, March 16, 2026).
Sell to companies like AN2 Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Almitas Capital LLC · Sole voting: 1,479,129 · Shared voting: 0 · Sole dispositive: 1,479,129 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-15
- · Reporting person: Commodore Capital LP · Sole voting: 0 · Shared voting: 3,697,435 · Sole dispositive: 0 · Shared dispositive: 3,697,435 · SCHEDULE 13G, 2026-03-16
- · Reporting person: Vivo Opportunity Fund Holdings, L.P. · Sole voting: 2,864,346 · Shared voting: 0 · Sole dispositive: 2,864,346 · Shared dispositive: 0 · SCHEDULE 13G, 2026-03-13
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 2,135,044 · Sole dispositive: 0 · Shared dispositive: 2,135,044 · SCHEDULE 13G, 2026-03-13
- · Holder: Almitas Capital LLC · Percent: 5.4% · SCHEDULE 13G
AN2 Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2025-11-14. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Commodore Capital LP | 9.9% | 3,697,435 | SCHEDULE 13G, 2026-03-16 | 2026-03-09 |
| Vivo Opportunity Fund Holdings, L.P. | 8% | 2,864,346 | SCHEDULE 13G, 2026-03-13 | 2026-03-10 |
| 7.9% | 2,232,004 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 | |
| Millennium Management LLC | 6.3% | 2,237,102 | SCHEDULE 13G, 2026-03-13 | 2026-03-06 |
| Almitas Capital LLC | 4.1% | 1,479,129 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind AN2 Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on AN2 Therapeutics, Inc. and the records around it.
AN2 Therapeutics, Inc. elsewhere on the record
- Form D filing Mar 2026
- Who owns it
Companies that share a holder
- Almitas Capital LLC also filed stake reports on 8 other companies: MFS HIGH YIELD MUNICIPAL TRUST (Aug 2026), MFS INVESTMENT GRADE MUNICIPAL TRUST (Aug 2026), ABRDN JAPAN EQUITY FUND, INC. (Feb 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
Watch AN2 Therapeutics, Inc.
Get an email when AN2 Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on AN2 Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on AN2 Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on AN2 Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Commodore Capital LP | 0 | 3,697,435 | 0 | 3,697,435 | SCHEDULE 13G, 2026-03-16 |
| Commodore Capital Master LP | 0 | 3,697,435 | 0 | 3,697,435 | SCHEDULE 13G, 2026-03-16 |
| Robert Egen Atkinson | 0 | 3,697,435 | 0 | 3,697,435 | SCHEDULE 13G, 2026-03-16 |
| Michael Kramarz | 0 | 3,697,435 | 0 | 3,697,435 | SCHEDULE 13G, 2026-03-16 |
| Vivo Opportunity Fund Holdings, L.P. | 2,864,346 | 0 | 2,864,346 | 0 | SCHEDULE 13G, 2026-03-13 |
| Vivo Opportunity, LLC | 2,864,346 | 0 | 2,864,346 | 0 | SCHEDULE 13G, 2026-03-13 |
| Vivo Opportunity Cayman Fund, L.P. | 289,294 | 0 | 289,294 | 0 | SCHEDULE 13G, 2026-03-13 |
| Vivo Opportunity Cayman, LLC | 289,294 | 0 | 289,294 | 0 | SCHEDULE 13G, 2026-03-13 |
| Integrated Core Strategies (US) LLC | 0 | 2,135,044 | 0 | 2,135,044 | SCHEDULE 13G, 2026-03-13 |
| Millennium Management LLC | 0 | 2,237,102 | 0 | 2,237,102 | SCHEDULE 13G, 2026-03-13 |
| Millennium Group Management LLC | 0 | 2,237,102 | 0 | 2,237,102 | SCHEDULE 13G, 2026-03-13 |
| Israel A. Englander | 0 | 2,237,102 | 0 | 2,237,102 | SCHEDULE 13G, 2026-03-13 |
| Almitas Capital LLC | 1,479,129 | 0 | 1,479,129 | 0 | SCHEDULE 13G/A, 2026-05-15 |
The latest filing identifies AN2 Therapeutics, Inc. by CUSIP 037326105 and gives its principal executive office as 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA 94025 (SCHEDULE 13G/A, 2026-05-15).
What the percentages are based on
See response to Item 11 on each cover page.Millennium Management LLC, SCHEDULE 13G, 2026-03-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-14 | Almitas Capital LLC | 5.2% | SCHEDULE 13G |
| 2026-02-13 | Eric Easom | 7.9% | SCHEDULE 13G/A |
| 2026-02-17 | Almitas Capital LLC | 5.4% | SCHEDULE 13G |
| 2026-03-13 | Millennium Management LLC | 6.3% | SCHEDULE 13G |
| 2026-03-13 | Vivo Opportunity Fund Holdings, L.P. | 8% | SCHEDULE 13G |
| 2026-03-16 | Commodore Capital LP | 9.9% | SCHEDULE 13G |
| 2026-05-15 | Almitas Capital LLC | 4.1% | SCHEDULE 13G/A |
Questions about who owns AN2 Therapeutics, Inc.
Who owns AN2 Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of AN2 Therapeutics, Inc.: Commodore Capital LP (9.9%, Schedule 13G, filed 2026-03-16), Vivo Opportunity Fund Holdings, L.P. (8%, Schedule 13G, filed 2026-03-13), Eric Easom (7.9%, Schedule 13G/A, filed 2026-02-13) and Millennium Management LLC (6.3%, Schedule 13G, filed 2026-03-13).
Who are the largest shareholders of AN2 Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of AN2 Therapeutics, Inc. on this page are Commodore Capital LP (9.9%), Vivo Opportunity Fund Holdings, L.P. (8%) and Eric Easom (7.9%).
When did Commodore Capital LP buy into AN2 Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Commodore Capital LP on this page is the Schedule 13G, filed 2026-03-16, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for AN2 Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| March 25, 2026 | Form D, private offering | $40M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for AN2 Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.